Loading
APC (Adenomatous polyposis coli protein) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Colorectal cancer, Gastric & gastro-oesophageal junction cancer, Hepatocellular carcinoma and 5 more. This dossier gathers the 0 products (0 approved), 0 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Tumour suppressor. Promotes rapid degradation of CTNNB1 and participates in Wnt signalling as a negative regulator. APC activity is correlated with its phosphorylation state. Activates the GEF activity of SPATA13 and ARHGEF4. Plays a role in hepatocyte growth factor (HGF)-induced cell migration. Required for MMP9 up-regulation via the JNK signalling pathway in colorectal tumour cells. Location: Cell junction, adherens junction; Cytoplasm, cytoskeleton; Cell projection, lamellipodium; Cell projection, ruffle membrane (UniProt). Locus 5q22.2 (HGNC).
| Cancer | Prevalence | Measure | Note | Source |
|---|---|---|---|---|
| Colorectal cancer | 58-77% | Inactivating mutation (WNT pathway gatekeeper) | cBioPortal: 5,400 of 7,237, 74.6%, in crc_msk_2026; 867 of 1,134, 76.5%, in crc_msk_2017; 1,145 of 1,516, 75.5%, in crc_eo_2020; 387 of 534, 72.5%, in coadread_tcga_pan_can_atlas_2018; 168 of 224, 75.0%, in coadread_tcga_pub; 361 of 619, 58.3%, in coadread_dfci_2016; 451 of 1,015, 44.4%, in crc_sysucc_2022. Deep deletion adds 40 of 7,237 (crc_msk_2026) and 18 of 592 (TCGA), and structural variants disrupt APC in a further 54 of 7,237 samples. The TCGA analysis found WNT signalling altered in 93% of tumours (Cancer Genome Atlas Network 2012); adding intronic APC splice alterations and large in-frame CTNNB1 deletions took oncogenic WNT alterations to 96% of 1,134 prospectively sequenced cancers (Yaeger 2018). | cBioPortal (TCGA) |
| Prostate cancer | 2-10% | Activating CTNNB1 exon 3 mutation, or APC inactivation | cBioPortal mutation: CTNNB1 89 of 2,260, 3.9%, in prostate_msk_2024; 23 of 424, 5.4%, in prad_mcspc_mskcc_2020; 19 of 444, 4.3%, in prad_su2c_2019; 11 of 494, 2.2%, in prad_tcga_pan_can_atlas_2018. APC mutation 176 of 2,260, 7.8%, in prostate_msk_2024; 36 of 424, 8.5%, in prad_mcspc_mskcc_2020; 31 of 444, 7.0%, in prad_su2c_2019, with deep deletion adding 1 to 10%. The CTNNB1 records cluster on the degron: in prostate_msk_2024, S37F 9, T41A 9, D32Y 7, T41I 7, S45P 6 of 94 records. | cBioPortal (TCGA) |
Approximate, population-level figures; the measure column says what was counted. Ranges show the midpoint as a bar.
No product in the corpus is aimed at this target yet.
No trial in the corpus names this target or one of its products.
No recorded escape route names this target.
No pathway diagram carries this target as a node.
No companion diagnostic in the registry measures this target.
No model entry for this target yet; check the cancer entries on the models page.
No open questions recorded for this target yet. Suggest one.
Query for this target: (TITLE:"APC" OR ABSTRACT:"APC" OR TITLE:"APC regulator of Wnt signaling pathway" OR ABSTRACT:"APC regulator of Wnt signaling pathway" OR TITLE:"Adenomatous polyposis coli protein" OR ABSTRACT:"Adenomatous polyposis coli protein" OR TITLE:"DP2" OR ABSTRACT:"DP2" OR TITLE:"DP3" OR ABSTRACT:"DP3" OR TITLE:"DP2.5" OR ABSTRACT:"DP2.5") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about APC, not a curated reading list.
The dossier as machine-readable JSON, at /api/v1/dossiers/apc.json: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/apc.json. Licence CC BY-NC 4.0.